UW logo
Human Subjects Division (HSD)


UW Researchers who are members of the Cancer Consortium

Oct 21, 2010 at 2:11pm

Reminder:   All human subjects research that is cancer-related and for which the principal investigator is a member of the Cancer Consortium must be reviewed by the Fred Hutchinson CC-IRB instead of the UW IRB.   There are two exceptions:

  • Repositories that are physically kept in UW owned, operated, or leased facilities.
  • Industry-initiated-and-sponsored clinical trials. (Investigators can chose whether to have these reviewed by the Hutch's CC-IRB or by WIRB.)

This arrangement between the UW and the Hutch began in 2005, to ensure that the IRB review of cancer-related studies is performed by individuals who have oncology experience and expertise.

New IRB applications.  Unless your research qualifies for one of the exceptions above, you must submit any new IRB applications to the Fred Hutch IRB, using the Fred Hutch IRB application. We have noticed recently that UW investigators who are new members of the Cancer Consortium are not consistently aware of this requirement. We have unfortunately received several applications to the UW IRB which we had to return, with the request that the investigator complete the Fred Hutch IRB application instead.

Existing IRB applications with the UW IRB.   When someone becomes a member of the Cancer Consortium, any existing IRB applications will be transferred to the CC-IRB about 12 weeks before expiration of IRB approval. The UW IRB and/or the CC-IRB will contact the investigators well in advance.

Exceptions to transfer from the UW to CC-IRB include:

  • Repositories (as described above)
  • Studies for which subject enrollment has been completed
  • Studies with exempt status.

If you have any questions, please contact Arna Elezovic at hsdinfo@u.washington.edu or 543-0639.